FY2016 EPS Estimates for Endo International PLC (ENDP) Boosted by William Blair
Endo International PLC (NASDAQ:ENDP) – William Blair lifted their FY2016 EPS estimates for shares of Endo International PLC in a research note issued on Wednesday. William Blair analyst T. Lugo now forecasts that the firm will post earnings of $4.75 per share for the year, up from their prior estimate of $4.55.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.20. The business had revenue of $894.30 million for the quarter, compared to analyst estimates of $862.47 million. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. Endo International PLC’s revenue was up 18.6% compared to the same quarter last year. During the same period last year, the firm posted $1.02 earnings per share.
Other equities research analysts also recently issued reports about the company. Vetr downgraded Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $18.57 target price for the company. in a report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price objective on Endo International PLC and gave the company a “buy” rating in a report on Tuesday, August 9th. Mizuho upgraded Endo International PLC from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $16.00 to $29.00 in a report on Friday, August 12th. Citigroup Inc. decreased their price objective on Endo International PLC from $40.00 to $25.00 and set a “buy” rating for the company in a report on Friday, September 16th. Finally, Guggenheim restated a “buy” rating and set a $35.00 price objective on shares of Endo International PLC in a report on Saturday, October 15th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.52.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Heartland Advisors Inc. purchased a new position in shares of Endo International PLC during the second quarter worth approximately $15,627,000. State Street Corp raised its stake in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock worth $147,021,000 after buying an additional 805,101 shares during the last quarter. Schneider Capital Management Corp bought a new stake in Endo International PLC during the second quarter worth about $6,941,000. Quantitative Investment Management LLC raised its stake in Endo International PLC by 166.2% in the second quarter. Quantitative Investment Management LLC now owns 654,800 shares of the company’s stock worth $10,208,000 after buying an additional 408,800 shares during the last quarter. Finally, Alps Advisors Inc. bought a new stake in Endo International PLC during the second quarter worth about $4,877,000. 96.61% of the stock is currently owned by hedge funds and other institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.